Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) shares saw an uptick in trading volume on Monday . 571,514 shares were traded during trading, an increase of 27% from the previous session’s volume of 449,303 shares.The stock last traded at $11.93 and had previously closed at $11.97.

A number of brokerages recently issued reports on MNTA. Brean Capital restated a “buy” rating and set a $19.00 price objective on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. JPMorgan Chase & Co. restated a “buy” rating on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Leerink Swann restated an “outperform” rating and set a $18.00 price objective (down previously from $21.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, April 27th. Finally, Goldman Sachs Group Inc. started coverage on shares of Momenta Pharmaceuticals in a report on Monday, June 6th. They issued a “neutral” rating and a $14.00 price target for the company. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $17.80.

The firm’s market capitalization is $810.13 million. The company has a 50-day moving average of $11.46 and a 200 day moving average of $10.39.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.01. The firm had revenue of $26.40 million for the quarter, compared to the consensus estimate of $23.55 million. The firm’s revenue for the quarter was down 41.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.04) EPS. On average, equities analysts forecast that Momenta Pharmaceuticals Inc. will post ($1.25) EPS for the current fiscal year.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 5,880 shares of the firm’s stock in a transaction that occurred on Friday, May 20th. The shares were sold at an average price of $10.18, for a total transaction of $59,858.40. Following the completion of the transaction, the president now owns 349,521 shares in the company, valued at approximately $3,558,123.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

A number of hedge funds and institutional investors have recently added to or reduced their stakes in MNTA. Morgan Stanley raised its position in Momenta Pharmaceuticals by 123.0% in the fourth quarter. Morgan Stanley now owns 69,759 shares of the biotechnology company’s stock valued at $1,035,000 after buying an additional 38,470 shares during the last quarter. New York State Common Retirement Fund raised its position in Momenta Pharmaceuticals by 2.0% in the fourth quarter. New York State Common Retirement Fund now owns 150,991 shares of the biotechnology company’s stock valued at $2,241,000 after buying an additional 2,900 shares during the last quarter. California Public Employees Retirement System raised its position in Momenta Pharmaceuticals by 2.9% in the fourth quarter. California Public Employees Retirement System now owns 200,600 shares of the biotechnology company’s stock valued at $2,977,000 after buying an additional 5,600 shares during the last quarter. Rhumbline Advisers raised its position in Momenta Pharmaceuticals by 9.9% in the fourth quarter. Rhumbline Advisers now owns 75,638 shares of the biotechnology company’s stock valued at $1,122,000 after buying an additional 6,835 shares during the last quarter. Finally, Swiss National Bank raised its position in Momenta Pharmaceuticals by 2.6% in the fourth quarter. Swiss National Bank now owns 91,500 shares of the biotechnology company’s stock valued at $1,358,000 after buying an additional 2,300 shares during the last quarter.

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.